Circulating biomarkers for early detection and clinical management of colorectal cancer
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
31189073
DOI
10.1016/j.mam.2019.06.002
PII: S0098-2997(19)30009-3
Knihovny.cz E-resources
- Keywords
- Cell-free DNA, Circulating tumor cells (CTC), Liquid biopsy, MicroRNA, Prognosis, Screening,
- MeSH
- Early Detection of Cancer MeSH
- Circulating MicroRNA MeSH
- Circulating Tumor DNA MeSH
- Colorectal Neoplasms blood diagnosis etiology therapy MeSH
- Humans MeSH
- Disease Management MeSH
- Biomarkers, Tumor blood MeSH
- Neoplastic Cells, Circulating MeSH
- Prognosis MeSH
- Liquid Biopsy methods MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Circulating MicroRNA MeSH
- Circulating Tumor DNA MeSH
- Biomarkers, Tumor MeSH
New non-invasive approaches that can complement and improve on current strategies for colorectal cancer (CRC) screening and management are urgently needed. A growing number of publications have documented that components of tumors, which are shed into the circulation, can be detected in the form of liquid biopsies and can be used to detect CRC at early stages, to predict response to certain therapies and to detect CRC recurrence in a minimally invasive way. The analysis of circulating tumor DNA (ctDNA), tumor-derived cells (CTC, circulating tumor cells) or circulating microRNA (miRNA) in blood and other body fluids, have a great potential to improve different aspects of CRC management. The challenge now is to find which types of components, biofluids and detection methods would be the most suitable to be applied in the different steps of CRC detection and treatment. This chapter will provide an up to date review on ctDNA, CTCs and circulating miRNAs as new biomarkers for CRC, either for clinical management or early detection, highlighting their advantages and limitations.
Department of Pathology Netherlands Cancer Institute Amsterdam the Netherlands
Molecular Oncology Laboratory Hospital Clinico San Carlos IdISSC CIBERONC Madrid Spain
References provided by Crossref.org
Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition
Colorectal Adenomas-Genetics and Searching for New Molecular Screening Biomarkers